Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.
Soft Tissue Sarcoma
Market Insight, Epidemiology and Market Forecast - 2030
Private and Confidential
Introduction to DelveInsight
To help organizations make important business
decisions through the ...
Lorem Ipsum is simply dummy text of the printing and typesetting industry.
Lorem Ipsum has been the industry's standard du...
A detailed review of Soft Tissue Sarcoma
market; historical and forecasted is
included in the report, covering drug
outrea...
D
D
Soft Tissue Sarcoma - Introduction
• Soft-tissue sarcoma (STS) are rare neoplasms that can develop in supporting or
co...
6
Soft Tissue Sarcoma
Epidemiology Insight
55+ Years
21-54 Year
<20
Age-Specific Incidence of STS in the US
0 1000 2000 3000 4000 5000 6000 7000 8000
Localized Type
...
8
Soft Tissue Sarcoma
Market Insight
11 Years
Forecast
7MM
Coverage
Epidemiology
Segmentation
Key Cross
Competition
Highly...
Lorem Ipsum is simply dummy text of
the printing and typesetting industry.
9
6.47%CAGR
Soft Tissue Sarcoma Market Size
is ...
Lorem Ipsum is simply dummy text of
the printing and typesetting industry.
10
Soft Tissue Sarcoma Market
172.52
182.56
188...
11
Soft Tissue Sarcoma
Emerging Therapies
Lorem Ipsum is simply dummy text of
the printing and typesetting industry.
12
Emerging Therapies
Avapritinib
Anlotinib
Sel...
Market Drivers & Barrier
Market Driver
Market Barrier
Competitive Landscape
Precision Medicine Approach
Novel Therapies fo...
KOL Opinion Analysis
Rare Disease Segment has scarcity of data through published literature, with statistical analysis als...
DelveInsight KOL Network
DelveInsight has an extensive KOL Network, from in-house experts to associated personnel, across ...
Pricing & Reimbursement
Related Reports
"Soft Tissue Sarcoma Pipeline Insight, 2020" report by DelveInsight outlays comprehensive insights of
pres...
Contact Us
+91-11-45689769
+1(919)-321-6187
info@delveinsight.com Click Here Click Here
Click Here to visit our Report Sto...
Thank You
You’ve finished this document.
Download and read it offline.
Upcoming SlideShare
What to Upload to SlideShare
Next
Upcoming SlideShare
What to Upload to SlideShare
Next
Download to read offline and view in fullscreen.

1

Share

Soft tissue Sarcoma Market

Download to read offline

DelveInsight’s ‘Soft Tissue Sarcoma Market Insights, Epidemiology, and Market Forecast-2030’ report deliver an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Soft Tissue Sarcoma (STS) in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

https://www.delveinsight.com/report-store/soft-tissue-sarcoma-market

The Soft Tissue Sarcoma market report provides analysis regarding current treatment practices, emerging drugs like AL3818, Fibromun, AL3818, Ripretinib, market share of the individual therapies, historical, current and forecasted Soft Tissue Sarcoma market Size from 2017 to 2030 segmented by seven major markets.

Related Books

Free with a 30 day trial from Scribd

See all

Related Audiobooks

Free with a 30 day trial from Scribd

See all

Soft tissue Sarcoma Market

  1. 1. Soft Tissue Sarcoma Market Insight, Epidemiology and Market Forecast - 2030
  2. 2. Private and Confidential Introduction to DelveInsight To help organizations make important business decisions through the use and analysis of actionable market intelligence. It is our mission to provide the most effective results and services coupled with acute client care to create a long- lasting relationship with our clients. Mission To become the most trusted marketing research & business consulting firm worldwide. To be a renowned and premier data driven solution providers among Pharma & Biotech companies. Vision Actionable Intelligence Shaping & Influencing the Strategic Thinking Accurate market assessment of competitors, products & technology provides DelveInsight insightful valuation of industry evolution. Understanding Industry Evolution Industry Experience In-depth knowledge of Healthcare Industry with focus on Pharmaceutical and Biotechnological Domain. Discovering liabilities for a more robust intelligence output, uncovering possible reasons for strategic failure, and work to avoid them. Blind spot Analysis Dedicated Monitoring Focused on current players tracking, as well as on monitoring new entrants for forecasting their impact on the market. Emphasis is on checking for any disruptive substitute in the market.
  3. 3. Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry's standard dummy text ever since the 1500s. KPI DashboardYour great subtitle in this line Lorem ipsum dolor sit amet, consectetur Drink Coffee Lorem ipsum dolor sit amet, consectetur Mobile Data Lorem ipsum dolor sit amet, consectetur Love Overview of pathophysiology, various diagnostic approaches and treatment algorithm including detailed chapters for marketed products and emerging therapies Detailed historical and forecasted market covering the United States, EU5, and Japan from 2017 to 2030 Pipeline analysis across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross -competition, launch date along with product development activities. Detailed Market size by therapies, covering the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom), and Japan from 2017 to 2030 Historical as well as forecasted epidemiology in 7MM covering the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom), and Japan from 2017 to 2030 Research Analysis Market Analysis Pipeline Valuation Market Size by Therapies Epidem Forecast Soft Tissue Sarcoma
  4. 4. A detailed review of Soft Tissue Sarcoma market; historical and forecasted is included in the report, covering drug outreach in the 7MM Comprehensive insight has been provided into the Soft Tissue Sarcoma epidemiology and treatment in the 7MM The report covers the descriptive overview of Soft Tissue Sarcoma, explaining its causes, signs and symptoms, pathophysiology and currently available therapies Additionally, an all-inclusive account of both the current and emerging therapies for Soft Tissue Sarcoma are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape 4 The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Soft Tissue Sarcoma market Scope Of Report
  5. 5. D D Soft Tissue Sarcoma - Introduction • Soft-tissue sarcoma (STS) are rare neoplasms that can develop in supporting or connective tissue, such as the muscle, nerves, tendons, blood vessels and fatty and fibrous tissues. They commonly affect the arms, legs, and trunk. They also appear in the stomach and intestines (GIST) as well as behind the abdomen (retroperitoneal sarcomas) and the female reproductive system (gynecological sarcomas). • STSs may be classified according to the involved cell-type, the specific nature of the malignancy, and the disease’s clinical course. According to the World Health Organization (WHO), there are more than 50 histologic subtypes of STSs. • The signs and symptoms of STSs vary greatly from patients to patients based on the type of STS. However, it is not associated with any noticeable symptoms early in the course of the disease but the affected individuals may notice slow- growing, painless mass in the affected area. • Many STSs associated with reciprocal translocations. Some forms of STS are associated with a variation (mutation) in a single oncogene, which is believed to drive the growth of cancer. An altered (mutation) oncogene may produce a protein that is ineffective, overproduced, or under-produced. Environmental factors that have been associated with STSs include radiation therapy and exposure to certain chemicals, including vinyl chloride, arsenic, and thorium dioxide.
  6. 6. 6 Soft Tissue Sarcoma Epidemiology Insight
  7. 7. 55+ Years 21-54 Year <20 Age-Specific Incidence of STS in the US 0 1000 2000 3000 4000 5000 6000 7000 8000 Localized Type Regional Type Distant Type Other Type Stage-Specific Incidence of STS in the US Stage-Specific Incidence of STS in the US According to DelveInsight’s analysts, in the US, localized stage accounted for 60% of overall STS cases in 2017. In 2017, there were 7,434 cases of localized type, 2,354 cases of regional type, 1,859 cases of regional type, and 743 cases of unknown type. Stage-Specific Incidence of STS in the US For DelveInsight’s epidemiology model, different age-groups are included: <20 years, 21–54 years, and 55 plus years. It is estimated that the most incident age-group for STS in the US was 55+ years in 2017. Patients of age groups 21–54 years were observed to be the second-highest, in 2017.
  8. 8. 8 Soft Tissue Sarcoma Market Insight 11 Years Forecast 7MM Coverage Epidemiology Segmentation Key Cross Competition Highly Analyzed Market Drugs Uptake
  9. 9. Lorem Ipsum is simply dummy text of the printing and typesetting industry. 9 6.47%CAGR Soft Tissue Sarcoma Market Size is Expected to Increase With a Soft Tissue Sarcoma Market XX XX XX US Germany France XX Italy XX XX XX Spain UK Japan MARKET SHARE SEGMENTATION OF 7MM COUNTRIES IN 2030
  10. 10. Lorem Ipsum is simply dummy text of the printing and typesetting industry. 10 Soft Tissue Sarcoma Market 172.52 182.56 188.81 195.29 201.87 208.25 182.17 158.66 138.15 119.88 103.96 89.22 76.96 65.80 48.68 51.54 53.31 55.16 57.02 58.77 60.68 62.7 63.58 64.47 65.32 66.01 67.1 68.23 10.72 11.29 11.64 12.01 12.37 12.67 13.02 13.35 13.71 14.05 14.35 14.56 14.9 15.2311.07 11.33 11.36 11.39 11.34 11.26 11.24 11.17 11.11 10.98 10.74 10.36 10.14 9.83 1.82 1.84 1.84 1.83 1.81 1.79 1.81 1.81 1.81 1.8 1.78 1.74 1.71 1.684.25 4.33 4.34 4.35 4.34 4.31 4.33 4.33 4.33 4.31 4.27 4.19 4.15 4.091.57 1.61 1.61 1.61 1.6 1.58 1.6 1.61 1.63 1.64 1.64 1.63 1.62 1.613.43 3.54 3.57 3.6 3.59 3.57 3.5 3.42 3.34 3.22 3.05 2.8 2.65 2.453.68 3.8 3.82 3.84 3.83 3.78 3.77 3.7 3.63 3.53 3.36 3.11 2.95 2.770.35 0.35 0.35 0.35 0.35 0.35 0.34 0.34 0.33 0.32 0.3 0.27 0.26 0.231.05 1.08 1.09 1.1 1.1 1.09 1.07 1.03 0.99 0.94 0.86 0.76 0.69 0.60.25 0.26 0.26 0.26 0.26 0.26 0.26 0.26 0.26 0.25 0.25 0.23 0.22 0.211.25 1.29 1.29 1.29 1.28 1.27 1.29 1.29 1.3 1.3 1.29 1.26 1.25 1.220.06 0.06 0.06 0.06 0.06 0.06 0.06 0.05 0.05 0.04 0.03 0.02 0.01 0.010.03 0.03 0.03 0.04 0.04 0.04 0.04 0.04 0.04 0.04 0.04 0.04 0.04 0.040.21 0.21 0.21 0.22 0.22 0.21 0.21 0.19 0.18 0.16 0.14 0.1 0.08 0.060.49 0.51 0.51 0.52 0.52 0.51 0.51 0.5 0.49 0.48 0.46 0.43 0.42 0.39 246.67 260.51 268.94 277.68 286.43 294.74 270.89 249.59 230.17 212.9 197.73 183.25 172.05 161.84 0 0 0 0 0 0 1.84 2.74 4.08 6.07 9.05 13.48 13.83 17.17 0 0 0 0 0 15.93 22.24 31.05 43.34 60.51 84.48 117.95 121.33 124.77 0 0 0 0 3.68 5.9 9.45 15.15 15.14 15.13 15.12 15.11 15.76 16.6 0 0 0 0 5.1 6.89 18.68 25.35 34.39 46.67 63.33 85.94 100.2 119.52 0 0 0 0 0 0 0 0 2 2.89 4.18 6.03 8.72 12.59 0 0 0 0 0 0 0 0 0 3.58 5.18 7.48 10.8 15.6 0 0 0 0 0 0 0 3.91 5.65 8.16 11.79 17.03 24.61 24.84 0 0 0 0 0 0 0 5.33 7.44 10.39 14.51 20.26 28.28 39.49 0 0 0 0 0 0 0 0 3.28 4.74 6.85 9.9 14.29 20.65 0 0 0 0 0 0 0 0.76 1.14 1.73 2.6 3.93 3.93 3.930.00 50.00 100.00 150.00 200.00 250.00 300.00 350.00 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 USDMillion Market Size of STS by therapies Votrient Yondelis Halaven Anthracycline Regimens other doxorubicin-based regimens doxorubicin, ifosfamide doxorubicin liposomal doxorubicin Non-anthracycline regimens ifosfamide-based regimens docetaxel gemcitabine gemcitabine, docetaxel ifosfamide gemcitabine, decarbazine paclitaxel other Total Current Revenue of STS (1L+2L+3L+4L) Vigil AL3818 Selinexor Fibromun GSK 3377794 Tazemetostat Abemaciclib Pembrolizumab Crizotinib ABI-009
  11. 11. 11 Soft Tissue Sarcoma Emerging Therapies
  12. 12. Lorem Ipsum is simply dummy text of the printing and typesetting industry. 12 Emerging Therapies Avapritinib Anlotinib Selinexor Ripretinib Crenolanib Fibromun GSK3377794 Companies CompaniesDrugs Drugs
  13. 13. Market Drivers & Barrier Market Driver Market Barrier Competitive Landscape Precision Medicine Approach Novel Therapies for Subtype of STS High Cost of Treatment Stringent Government Regulations High Failure Rate in the Clinical Trials
  14. 14. KOL Opinion Analysis Rare Disease Segment has scarcity of data through published literature, with statistical analysis also having dearth of information. DelveInsight surpasses this challenge through its extensive Primary Research, through its association with Key Opinion Leaders across the Globe R&D Assessment KOLs include Research Scientists, Clinical Trial Investigators, Research Nurses, General Practitioners, Medical Consultants, as well as Specialty Physicians Epidemiology Assessment KOLs include Epidemiologists, Company Personnel, Disease Organizations’ Executives, Medical Consultants, Consulting analysts, as well as Specialty Physicians etc. Market Assessment KOLs include Financial Analysts, Freelance Consultants, Company Personnel, B Consulting analysts, as well as Specialty Physicians etc.
  15. 15. DelveInsight KOL Network DelveInsight has an extensive KOL Network, from in-house experts to associated personnel, across all geographies, who provide accurate and real time insights on the research needs of DelveInsight’s clients Our Extensive Coverage of the Healthcare Industry can be assessed from our reach across the Global Markets Our External panel consists of our associations with Key Opinion Leaders on Project basis, where we recruit key personnel related to the therapy area/disease area in question to assess thoughts on the Industry Trends Our internal panel consists of Dr. BK Agrawal and his associations of Pharma Consultants, Medical Doctors and Industry Leaders
  16. 16. Pricing & Reimbursement
  17. 17. Related Reports "Soft Tissue Sarcoma Pipeline Insight, 2020" report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Soft Tissue Sarcoma market. A detailed picture of the Soft Tissue Sarcoma pipeline landscape is provided, which includes the disease overview and Soft Tissue Sarcoma treatment guidelines.  Soft Tissue Sarcoma - Pipeline Insights, 2020  Soft Tissue Sarcoma - Epidemiology Forecast to 2030 DelveInsight's 'Soft Tissue Sarcoma - Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical and forecasted Soft Tissue Sarcoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
  18. 18. Contact Us +91-11-45689769 +1(919)-321-6187 info@delveinsight.com Click Here Click Here Click Here to visit our Report Store
  19. 19. Thank You
  • DRAMNAHASSAN

    Jul. 24, 2021

DelveInsight’s ‘Soft Tissue Sarcoma Market Insights, Epidemiology, and Market Forecast-2030’ report deliver an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Soft Tissue Sarcoma (STS) in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. https://www.delveinsight.com/report-store/soft-tissue-sarcoma-market The Soft Tissue Sarcoma market report provides analysis regarding current treatment practices, emerging drugs like AL3818, Fibromun, AL3818, Ripretinib, market share of the individual therapies, historical, current and forecasted Soft Tissue Sarcoma market Size from 2017 to 2030 segmented by seven major markets.

Views

Total views

40

On Slideshare

0

From embeds

0

Number of embeds

0

Actions

Downloads

0

Shares

0

Comments

0

Likes

1

×